Compare NBTB & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBTB | ALMR |
|---|---|---|
| Founded | 1856 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 1995 | 2026 |
| Metric | NBTB | ALMR |
|---|---|---|
| Price | $51.67 | $27.64 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $51.33 | N/A |
| AVG Volume (30 Days) | 211.4K | ★ 269.0K |
| Earning Date | 04-23-2026 | N/A |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | ★ 12.12 | N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $182,952,000.00 | N/A |
| Revenue This Year | $16.82 | N/A |
| Revenue Next Year | $4.88 | N/A |
| P/E Ratio | $25.70 | ★ N/A |
| Revenue Growth | ★ 10.40 | N/A |
| 52 Week Low | $39.21 | $21.58 |
| 52 Week High | $54.50 | $38.54 |
| Indicator | NBTB | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 45.47 | 40.02 |
| Support Level | $50.40 | $23.69 |
| Resistance Level | $53.67 | $28.35 |
| Average True Range (ATR) | 0.74 | 1.94 |
| MACD | -0.09 | -0.74 |
| Stochastic Oscillator | 44.79 | 1.60 |
NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.